Despite inquiry, FDA AdCom backs BMS Abecma approval
AdCom voted eight to three in favour of BMS and 2seventy bio’s CAR-T cell therapy, Abecma, in triple-class exposed multiple myeloma patients.
AdCom voted eight to three in favour of BMS and 2seventy bio’s CAR-T cell therapy, Abecma, in triple-class exposed multiple myeloma patients.
The funds will be used to expand the company’s headcount and enhance datasets.
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms,...
Tierra raises $11.4 in Series A round for predictive AI protein maker
CTS Europe: The roadmap for generative AI in the pharma industry
Sonrai Analytics and Candel to advance cancer treatment using AI
1910 Genetics and Microsoft partner to enhance pharmaceutical R&D